loder, who hasn't been involved with any cgrp drug studies, cautions that these medicines don't work for everybody. and they may be risky for some people..
"it's a very exciting time," klugman said. "this is exactly where we would like prenatal diagnosis to go -- to be able to act on it.".
in a news release, the drug's manufacturer, amgen, said the list price will be 5 a month or ,900 annually. costs to patients may vary depending on insurance...